Sage Group plc Unsponsored ADR (SGPYY)
OTC PINK OTC PINK Primary 
Sage Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAGE
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-06511, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sage securities between April 12, 2021 and July 23, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Sage Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Shareholders of Sage Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Investors in Sage Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE
NEW YORK, NY / ACCESSWIRE / October 20, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Sage Therapeutics Inc
LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAGE
NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-06511, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sage securities between April 12, 2021 and July 23, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Sage Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.
Sage Therapeutics to Reduce Workforce by 33%, Stock Down
SAGE announces a portfolio reprioritization plan to focus on the launch of the depression drug Zurzuvae and other pipeline developments. Stock falls in after-hours trading.
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Sage Therapeutics Inc
LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.
Sage Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.
Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard.
The biopharmaceutical company says the reorganization is meant to strengthen its balance sheet and position it for long-term growth.
